Low‐density lipoprotein and other predictors of response with telaprevir‐based therapy in treatment‐experienced HCV genotype 1 patients: REALIZE study

Publisher： John Wiley & Sons Inc

E-ISSN： 1478-3231|35|2|448-454

ISSN： 1478-3223

Source： LIVER INTERNATIONAL (ELECTRONIC), Vol.35, Iss.2, 2015-02, pp. : 448-454

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Factors associated with sustained virological response in 24‐week telaprevir‐based triple therapy for chronic hepatitis C genotype 1b patients with the IL28B minor genotype

By  

HEPATOLOGY RESEARCH, Vol. 45, Iss. 4, 2015-04 ,pp. : 387-396

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy of telaprevir‐based therapy for difficult‐to‐treat patients with genotype 2 chronic hepatitis C in Japan

By  

HEPATOLOGY RESEARCH, Vol. 45, Iss. 7, 2015-07 ,pp. : 745-754

John Wiley & Sons Inc

Access to resources Recommend Favorite

The real impact of telaprevir dosage on the antiviral and side effects of telaprevir, pegylated interferon and ribavirin therapy for chronic hepatitis C patients with HCV genotype 1

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 22, Iss. 3, 2015-03 ,pp. : 254-262

John Wiley & Sons Inc

Access to resources Recommend Favorite

Triple therapy with boceprevir or telaprevir in a European cohort of cirrhotic HIV/HCV genotype 1‐coinfected patients

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 35, Iss. 9, 2015-09 ,pp. : 2090-2099

John Wiley & Sons Inc

Access to resources Recommend Favorite

Telaprevir‐based triple therapy for chronic hepatitis C patients with advanced fibrosis: a prospective clinical study

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 38, Iss. 9, 2013-11 ,pp. : 1076-1085

John Wiley & Sons Inc

Access to resources Recommend Favorite